Current and future pharmacotherapy for alopecia areata

Bibliography

• SAMirzoyev, AGSchrum, MDDavis, et al. Lifetime incidence risk of Alopecia Areata estimated at 2.1 percent by Rochester Epidemiology Project, 1990–2009. J Invest Dermatol 2014;134(4):1141-2
   PubMed Web of Science ®Google Scholar
• MGalán-Gutiérrez, ARodríguez-Bujaldón, JCMoreno-Giménez. Update on the treatment of alopecia areata. Actas Dermosifiliogr 2009;100(4):266-76
   PubMedGoogle Scholar
• AGilhar, AEtzioni, RPaus. Alopecia Areata. NEJM 2012;366:1515-26
   PubMed Web of Science ®Google Scholar
• ATosti, RMorelli, FBardazzi, et al. Prevalence of nail abnormalities in children with alopecia areata. Pediatr Dermatol 1994;11(2):112-15
   PubMed Web of Science ®Google Scholar
• WIDotz, CDLieber, PJVogt. Leukonychia punctata and pitted nails in alopecia areata. Arch Dermatol 1985;121(11):1452-4
   PubMedGoogle Scholar
• MMiteva, ATosti. Hair and scalp dermatoscopy. J Am Acad Dermatol 2012;67(5):1040-8
   PubMed Web of Science ®Google Scholar
• MMarwah, NNadkarni, SPatil. ‘Ho-ver’ing Over Alopecia Areata: histopathological Study of 50 Cases. Int J Trichology 2014;6(1):13-18
   PubMedGoogle Scholar
• DAWhiting. Histopathologic features of alopecia areata: a new look. Arch Dermatol 2003;139(12):1555-9
   PubMed Web of Science ®Google Scholar
• KPHuang, SMullangi, YGuo, et al. Autoimmune, Atopic, and Mental Health Comorbid Conditions Associated With Alopecia Areata in the United States. JAMA Dermatol 2014;149(7):789-94
   Google Scholar
• AGhanizadeh, AAyoobzadehshirazzi. A review of psychiatric disorders comorbidities in patients with alopecia areata. Int J Trichology 2014;6(1):2-4
   PubMedGoogle Scholar
• AAlkhalifah, AAlsantali, EWang, et al. Alopecia areata update. J Am Dermatology 2010;62(2):191-202
   PubMed Web of Science ®Google Scholar
• PHealth, NYork. The genetics of alopecia areata: what s new and how will it help our patients? Dermatol Ther 2011;24:326-36
   PubMedGoogle Scholar
• TIto, HHashizume, TShimauchi, et al. CXCL10 produced from hair follicles induces Th1 and Tc1 cell infiltration in the acute phase of alopecia areata followed by sustained Tc1 accumulation in the chronic phase. J Dermatol Sci 2013;69(2):140-7
   PubMed Web of Science ®Google Scholar
• SOno, AOtsuka, YYamamoto, et al. Serum granulysin as a possible key marker of the activity of alopecia areata. J Dermatol Sci 2014;73(1):74-9
   PubMed Web of Science ®Google Scholar
• TIto. Recent advances in the pathogenesis of autoimmune hair loss disease alopecia areata. Clin Dev Immunol 2013;2013:348546
   PubMedGoogle Scholar
• EDCetin, ESavk, MUslu, et al. Investigation of the inflammatory mechanisms in alopecia areata. Am J Dermatopathol 2009;31(1):53-60
   PubMedGoogle Scholar
• TAWaldmann. The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders. J Investig Dermatol Symp Proc 2013;16(1):S28-30
   Google Scholar
• NIto, TIto, AKromminga, et al. Human hair follicles display a functional equivalent of the hypothalamic-pituitary-adrenal axis and synthesize cortisol. FASEB J 2005;19(10):1332-4
   PubMedGoogle Scholar
• XZhang, MYu, WYu, et al. Development of alopecia areata is associated with higher central and peripheral hypothalamic-pituitary-adrenal tone in the skin graft induced C3H/HeJ mouse model. J Invest Dermatol 2009;129(6):1527-38
   PubMed Web of Science ®Google Scholar
• EMPeters, SLiotiri, EBodó, et al. Probing the effects of stress mediators on the human hair follicle: substance P holds central position. Am J Pathol 2007;171(6):1872-86
   PubMedGoogle Scholar
• VABotchkarev. Neurotrophins and their role in pathogenesis of alopecia areata. J Investig Dermatol Symp Proc 2003;8(2):195-8
   PubMedGoogle Scholar
• DWasserman, DAGuzman-Sanchez, KScott, et al. Alopecia areata. Int J Dermatol 2007;46(2):121-31
   PubMedGoogle Scholar
• EKubeyinje. Intralesional triamcinolone acetonide in alopecia areata amongst 62 Saudi Arabs. East Afr Med J 1994;71(10):674-65
   PubMed Web of Science ®Google Scholar
• BDe Souza, GBantick. Anaphylactic reaction to intralesional steroid injection. Plast Reconstr Surg 2006;117(1):336
   PubMedGoogle Scholar
• MLaing, BFallis, GMurphy. Anaphylactic reaction to intralesional corticosteroid injection. Contact Dermat 2007;57:132-3
   PubMedGoogle Scholar
• ADowns, JLear, CKennedy. Anaphylaxis to intradermal triamcinolone acetonide. Arch Dermatol 1998;134:1163-4
   PubMedGoogle Scholar
• ASamrao, JMFu, STHarris, et al. Bone mineral density in patients with alopecia areata treated with long-term intralesional corticosteroids. J Drugs Dermatology 2013;12(2):e36-40
   Google Scholar
• BKrafchik, JDegroot, AKhambalia, et al. Clobetasol Propionate, 0.05%, vs Hydrocortisone, 1%, for Alopecia Areata in Children A Randomized Clinical Trial. JAMA Dermatology 2014;150(1):47-50
   PubMedGoogle Scholar
• ATosti, MIorizzo, GLBotta, et al. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venereol 2006;20(10):1243-7
   PubMed Web of Science ®Google Scholar
• GMancuso, ABalducci, CCasadio, et al. Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in the treatment of mild-to-moderate alopecia areata: A multicenter, prospective, randomized , controlled, investigator-blinded trial. International Journal of Dermatology 2003;42:572-5
   PubMed Web of Science ®Google Scholar
• ATosti, BMPiraccini, MPazzaglia, et al. Clobetasol propionate 0.05% under occlusion in the treatment of alopecia totalis/universalis. J Am Acad Dermatol 2003;49(1):96-8
   PubMed Web of Science ®Google Scholar
• RHapple, HMKlein, EMacher. Topical immunotherapy changes the composition of the peribulbar infiltrate in alopecia areata. Arch Dermatol Res 1986;278(3):214-18
   PubMedGoogle Scholar
• AKohchiyama, AHatamochi, HUeki. Increased number of OKT6-positive dendritic cells in the hair follicles of patients with alopecia areata. Dermatologica 1985;171(5):327-31
   PubMedGoogle Scholar
• RMarhaba, MVitacolonna, DHildebrand, et al. The importance of myeloid-derived suppressor cells in the regulation of autoimmune effector cells by a chronic contact eczema. J Immunol 2007;179(8):5071-81
   PubMed Web of Science ®Google Scholar
• AGMessenger, JMcKillop, PFarrant, et al. British association of dermatologists’ guidelines for the management of alopecia areata 2012. Br J Dermatol 2012;166(5):916-26
   PubMed Web of Science ®Google Scholar
• LTang, LCao, SJp, et al. Restoration of hair growth in mice with an alopecia areata-like disease using topical anthralin. Exp Dermatol 2004;13(1):5-10
   PubMedGoogle Scholar
• VCFiedler-weiss. Evaluation of anthralin in the treatment of alopecia areata. Arch Dermatology 1987;123:21-3
   PubMedGoogle Scholar
• JShapiro. Current treatment of alopecia areata. J Investig Dermatol Symp Proc 2013;16(1):S42-4
   PubMedGoogle Scholar
• AElise, SCCarson, EATurney. Systemic steroids with or without 2 % topical minoxidil in the treatment of alopecia areata. Arch Dermatol 1992;128(11):1467-73
   PubMedGoogle Scholar
• MKurosawa, SNakagawa, MMizuashi, et al. A comparison of the efficacy, relapse rate and side effects among three modalities of systemic corticosteroid therapy for alopecia areata. Dermatology 2006;212(4):361-5
   PubMed Web of Science ®Google Scholar
• IRoseborough, HLee, JChwalek, et al. Lack of efficacy of topical latanoprost and bimatoprost ophthalmic solutions in promoting eyelash growth in patients with alopecia areata. J Am Acad Dermatol 2009;60(4):705-6
   PubMed Web of Science ®Google Scholar
• SMansberger, GCloffi. Eyelash formation secondary to Latanoprost treatment in a patient with alopecia. Arch Ophthalmol 2014;118(2000):718-22
   Google Scholar
• JSMehta, JRaman, NGupta, et al. Cutaneous latanoprost in the treatment of alopecia areata. Eye (Lond) 2003;17(3):444-6
   PubMedGoogle Scholar
• KJWhitmont, AJCooper. PUVA treatment of alopecia areata totalis and universalis: a retrospective study. Australas J Dermatol 2003;44(2):106-9
   PubMedGoogle Scholar
• ZMohamed, ABhouri, AJallouli, et al. Alopecia areata treatment with a phototoxic dose of UVA and topical 8-methoxypsoralen. J Eur Acad Dermatol Venereol 2005;19(5):552-5
   PubMed Web of Science ®Google Scholar
• SBehrens, ULeiter, RSchiener, et al. The PUVA-turban as a new option of applying a dilute psoralen solution selectively to the scalp of patients with alopecia areata. JAAD 2001;44(2):248-52
   PubMedGoogle Scholar
• SCBehrens-Williams, ULeiter, RSchiener, et al. The PUVA-turban as a new option of applying a dilute psoralen solution selectively to the scalp of patients with alopecia areata. J Am Acad Dermatol 2001;44(2):248-52
   PubMedGoogle Scholar
• DBayramgürler, EODemirsoy, AŞAktürk, et al. Narrowband ultraviolet B phototherapy for alopecia areata. Photodermatol Photoimmunol Photomed 2011;27(6):325-7
   PubMed Web of Science ®Google Scholar
• WZakaria, TPasseron, NOstovari, et al. 308-Nm Excimer Laser Therapy in Alopecia Areata. J Am Acad Dermatol 2004;51(5):837-8
   PubMed Web of Science ®Google Scholar
• NAl-Mutairi. 308-Nm Excimer Laser for the Treatment of Alopecia Areata. Dermatol Surg 2007;33(12):1483-7
   PubMed Web of Science ®Google Scholar
• AJMcMichael. Excimer laser: a module of the alopecia areata common protocol. J Investig Dermatol Symp Proc 2013;16(1):S77-9
   PubMedGoogle Scholar
• MIssa, MPires, PSilveira, et al. Transepidermal drug delivery: a new treatment option for areata alopecia? J Cosmet Laser Ther 2014;17(1):1-4
   Google Scholar
• TCWikramanayake, RRodriguez, SChoudhary, et al. Effects of the Lexington LaserComb on hair regrowth in the C3H/HeJ mouse model of alopecia areata. Lasers Med Sci 2012;27(2):431-6
   PubMed Web of Science ®Google Scholar
• LEKing, KASilva, VEKennedy, et al. Lack of response to laser comb in spontaneous and graft-induced alopecia areata in C3H/HeJ mice. J Invest Dermatol 2014;134(1):264-6
   PubMedGoogle Scholar
• GAçıkgöz, HYeşil, EÇalışkan, et al. Targeted photochemotherapy in alopecia areata. Photodermatol Photoimmunol Photomed 2013;29(6):318-22
   PubMedGoogle Scholar
• RBissonnette, JShapiro, HZeng, et al. Topical photodynamic therapy with 5-aminolaevulinic acid does not induce hair regrowth in patients with extensive alopecia areata. Br J Dermatol 2000;143(5):1032-5
   PubMedGoogle Scholar
• PGCalzavara-Pinton, MTRossi, EAronson, et al. A retrospective analysis of real-life practice of off-label photodynamic therapy using methyl aminolevulinate (MAL-PDT) in 20 Italian dermatology departments. Part 1: inflammatory and aesthetic indications. Photochem Photobiol Sci 2013;12(1):148-57
   PubMedGoogle Scholar
• MFernández-Guarino, AHarto, IGarcía-Morales, et al. Failure to treat alopecia areata with photodynamic therapy. Clin Exp Dermatol 2008;33(5):585-7
   PubMedGoogle Scholar
• TNakajima, SInui, SItami. Pulse corticosteroid therapy for alopecia areata: study of 139 Patients. 2007;215(4):320-4
   Google Scholar
• JLBurton, SShuster. Large doses of glucocorticoid in the treatment of alopecia areata. Acta Derm Venereol 1975;55(6):493-6
   PubMedGoogle Scholar
• MAit Ourhroui, BHassam, IKhoudri. Treatment of alopecia areata with prednisone in a once-monthly oral pulse. Ann Dermatol Venereol 2010;137(8–9):514-18
   PubMedGoogle Scholar
• BRKar, SHanda, SDogra, et al. Placebo-controlled oral pulse prednisolone therapy in alopecia areata. J Am Acad Dermatol 2005;52(2):287-90
   PubMed Web of Science ®Google Scholar
• FKern, WHHoffman, GWHambrick, et al. Alopecia areata. Immunologic studies and treatment with prednisone. Arch Dermatol 1973;107(3):407-12
   PubMedGoogle Scholar
• RJWinter, FKern, RMBlizzard. Prednisone therapy for alopecia areata. A follow-up report. Arch Dermatol 1976;112(11):1549-52
   PubMedGoogle Scholar
• VKSharma. Pulsed administration of corticosteroids in the treatment of alopecia areata. Int J Dermatol 1996;35(2):133-6
   PubMed Web of Science ®Google Scholar
• AFriedli, MPLabarthe, EEngelhardt, et al. Pulse methylprednisolone therapy for severe alopecia areata: an open prospective study of 45 patients. J Am Acad Dermatol 1998;39(4):597-602
   PubMedGoogle Scholar
• RFriedland, RTal, MLapidoth, et al. Pulse corticosteroid therapy for alopecia areata in children: a retrospective study. Dermatology 2013;227(1):37-44
   PubMed Web of Science ®Google Scholar
• GAçıkgöz, IOzmen, MCayırlı, et al. Pulse methylprednisolone therapy for the treatment of extensive alopecia areata. J Dermatolog Treat 2014;25(2):164-6
   PubMed Web of Science ®Google Scholar
• DStaumont-Sallé, MVonarx, FLengrand, et al. Pulse corticosteroid therapy for alopecia areata: long-term outcome after 10 years. Dermatology 2012;225(1):81-7
   PubMedGoogle Scholar
• PEfentaki, AAltenburg, JHaerting, et al. Medium-dose prednisolone pulse therapy in alopecia areata. Dermatoendocrinol 2009;1(6):310-13
   PubMedGoogle Scholar
• JShapiro, HLui, VTron, et al. Systemic cyclosporine and low-dose prednisone in the treatment of chronic severe alopecia areata: a clinical and immunopathologic evaluation. J Am Acad Dermatol 1997;36(1):114-17
   PubMed Web of Science ®Google Scholar
• BJKim, SUMin, KYPark, et al. Combination therapy of cyclosporine and methylprednisolone on severe alopecia areata. J Dermatolog Treat 2008;19(4):216-20
   PubMed Web of Science ®Google Scholar
• MShaheedi-Dadras, AKarami, FMollaei, et al. The effect of methylprednisolone pulse-therapy plus oral cyclosporine in the treatment of alopecia totalis and universalis. Arch Iran Med 2008;11(1):90-3
   PubMed Web of Science ®Google Scholar
• CNEllis, MFBrown, JJVoorhees. Sulfasalazine for alopecia areata. J Am Acad Dermatol 2002;46(4):541-4
   PubMedGoogle Scholar
• LMisery, KSannier, MChastaing, et al. Treatment of alopecia areata with sulfasalazine. J Eur Acad Dermatol Venereol 2007;21(4):547-8
   PubMedGoogle Scholar
• OBakar, OGurbuz. Is there a role for sulfasalazine in the treatment of alopecia areata? J Am Acad Dermatol 2007;57(4):703-6
   PubMedGoogle Scholar
• TRashidi, AAMahd. Treatment of persistent alopecia areata with sulfasalazine. Int J Dermatol 2008;47(8):850-2
   PubMedGoogle Scholar
• CDroitcourt, BMilpied, KEzzedine, et al. Interest of high-dose pulse corticosteroid therapy combined with methotrexate for severe alopecia areata: a retrospective case series. Dermatology 2012;224(4):369-73
   PubMed Web of Science ®Google Scholar
• EChartaux, PJoly. Long-term follow-up of the efficacy of methotrexate alone or in combination with low doses of oral corticosteroids in the treatment of alopecia areata totalis or universalis. Ann Dermatol Venereol 2010;137(8–9):507-13
   PubMed Web of Science ®Google Scholar
• MRoyer, CBodemer, PVabres, et al. Efficacy and tolerability of methotrexate in severe childhood alopecia areata. Br J Dermatol 2011;165(2):407-10
   PubMed Web of Science ®Google Scholar
• SFarshi, PMansouri, FSafar, et al. Could azathioprine be considered as a therapeutic alternative in the treatment of alopecia areata? A pilot study. Int J Dermatol 2010;49(10):1188-93
   PubMedGoogle Scholar
• RWillemsen, JVanderlinden, ADeconinck, et al. Hypnotherapeutic management of alopecia areata. J Am Acad Dermatol 2006;55(2):233-7
   PubMedGoogle Scholar
• MGautam. Alopecia due to psychotropic medications. Ann Pharmacother 2014;33:631-7
   Google Scholar
• GPerini, MZara, RCipriani, et al. Imipramine in alopecia areata. A double-blind, placebo-controlled study. Psychother Psychosom 1994;61(3–4):195-8
   PubMedGoogle Scholar
• RCipriani, GIPerini, SRampinelli. Paroxetine in alopecia areata. Int J Dermatol 2001;40(9):600-1
   PubMedGoogle Scholar
• MPPhilpott, DASanders, JBowen, et al. Effects of interleukins, colony-stimulating factor and tumour necrosis factor on human hair follicle growth in vitro: a possible role for interleukin-1 and tumour necrosis factor-alpha in alopecia areata. Br J Dermatol 1996;135(6):942-8
   PubMed Web of Science ®Google Scholar
• NPelivani, ASHassan, LRBraathen, et al. Alopecia areata universalis elicited during treatment with adalimumab. Dermatology 2008;216(4):320-3
   PubMedGoogle Scholar
• WPosten, JSwan. Recurrence of alopecia areata in a patient receiving etanercept injections. Arch Dermatol 2005;141(6):759-60
   PubMedGoogle Scholar
• BEStrober, KSiu, AFAlexis, et al. Etanercept does not effectively treat moderate to severe alopecia areata: an open-label study. J Am Acad Dermatol 2005;52(6):1082-4
   PubMedGoogle Scholar
• MTauber, SBuche, PReygagne, et al. Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study. J Am Acad Dermatol 2014;70(6):1146-9
   PubMed Web of Science ®Google Scholar
• SLindsey, ATosti. Hair Loss Induced by Tumor Necrosis Factor Alpha Inhibitors. J Clin Investig Dermatol 2013;100(1):1-6
   Google Scholar
• LGorcey, EASpratt, MCLeger. Alopecia universalis successfully treated with adalimumab. JAMA dermatology 2014;150(12):1341-4
   PubMedGoogle Scholar
• YXu, HZhuang, SHan, et al. Mechanisms of tumor necrosis factor α antagonist-induced lupus in a murine model. Arthritis Rheumatol 2015;67(1):225-37
   PubMed Web of Science ®Google Scholar
• MGhoreishi, MMartinka, JPDutz. Type 1 interferon signature in the scalp lesions of alopecia areata. Br J Dermatol 2010;163(1):57-62
   PubMed Web of Science ®Google Scholar
• MPHeffernan, MYHurley, KSMartin, et al. Alefacept for Alopecia Areata. Arch Dermatol 2005;141(12):16-19
   Google Scholar
• KBui, SPolisetty, HGilchrist, et al. Successful treatment of alopecia universalis with alefacept: a case report and review of the literature. Cutis 2008;81(5):431-4
   PubMed Web of Science ®Google Scholar
• BEStrober, KMenon, AMcmichael, et al. Alefacept for Severe Alopecia Areata. Arch Dermatology 2009;145(11):1262-6
   PubMedGoogle Scholar
• EZorn, MMohseni, HKim, et al. Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009;15(3):382-8
   PubMed Web of Science ®Google Scholar
• ECastela, FLe Duff, CButori, et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA dermatology 2014;150(7):748-51
   PubMed Web of Science ®Google Scholar
• TMeyer, UVinkemeier. Nucleocytoplasmic shuttling of STAT transcription factors. Eur J Biochem 2004;4612:4606-12
   Google Scholar
• NFreitas, CCunha. Mechanisms and Signals for the Nuclear Import of Proteins. Curr Genomics 19:550-7.2009
   Google Scholar
• SMHolland, LMStaudt. JAKs and STATs in Immunity, Immunodeficiency, and Cancer. NEJM 2013;368:161-70
   PubMedGoogle Scholar
• LAMacfarlane, DJTodd. Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis. Int J Rheum Dis 2014;17:359-68
   PubMed Web of Science ®Google Scholar
• AOstojic, RVrhovac, SVerstovsek. Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Ther Clin Risk Manag 2012;8:95-103
   PubMed Web of Science ®Google Scholar
• LXing, ZDai, AJabbari, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 2014;20(9):1043-9
   PubMed Web of Science ®Google Scholar
• LPieri, PGuglielmelli, AMVannucchi. Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. Am J Hematol 2014;90(1):82-3
   Google Scholar
• NPunwani, PScherle, RFlores, et al. Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis. JAAD 2011;67(4):658-64
   Google Scholar
• DVyas, KO’Dell, JBandy, et al. Tofacitinib: the First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother 2013;47(11):1524-31
   PubMed Web of Science ®Google Scholar
• WCPorts, SKhan, SLan, et al. A randomized Phase IIa efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 2013;169(1):137-45
   PubMed Web of Science ®Google Scholar
• LMLundquist, SWCole, MLSikes. Efficacy and safety of tofacitinib for treatment of rheumatoid arthritis. World J Orthop 2014;5(4):504-11
   PubMedGoogle Scholar
• MGBoy. Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690, 550 in patients with psoriasis. J Invest Dermatol 2009;129(9):2299-302
   PubMed Web of Science ®Google Scholar
• BGCraiglow, BAKing. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol 2014;134(12):2988-90
   PubMed Web of Science ®Google Scholar
• SRyu, YLee, MYHyun, et al. Mycophenolate antagonizes IFN-γ-induced catagen-like changes via β-catenin activation in human dermal papilla cells and hair follicles. Int J Mol Sci 2014;15(9):16800-15
   PubMedGoogle Scholar
• SSkurkovich, NGKorotky, NMSharova, et al. Treatment of alopecia areata with anti-interferon-γ antibodies. J Investig Dermatol Symp Proc 2005;10(3):283-4
   PubMedGoogle Scholar
• YZhao. Stem cell educator therapy and induction of immune balance. Curr Diab Rep 2012;12(5):517-23
   PubMedGoogle Scholar
• ATrink, ESorbellini, PBezzola, et al. A randomized, double-blind, placebo- and active-controlled, half-head study to evaluate the effects of platelet-rich plasma on alopecia areata. Br J Dermatol 2013;169(3):690-4
   PubMed Web of Science ®Google Scholar
• MMahamid, OAbu-Elhija, MSamamra, et al. Association between vitamin D levels and alopecia areata. Isr Med Assoc J 2014;16(6):367-70
   PubMed Web of Science ®Google Scholar
• JGreenwood, LSteinman, SSZamvil. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006;6:358-70
   PubMed Web of Science ®Google Scholar
• CBallantyne, PRidker, TPerson. Effects of ezetimibe/simvastatin compared to simvastatin monotherapy in reducing C-reactive protein and low density lipoprotein-cholesterol. J Am Coll Cardiol 2006;4(Suppl A):316A
   Google Scholar
• DNRobins. Alopecia Universalis: hair growth following initiation of Simvastatin and Ezetimibe therapy. J Drugs Dermatology 2007;6(9):946-7
   PubMedGoogle Scholar
• AAli, JMMartin. Hair Growth in Patients With Alopecia Areata Totalis After Treatment With Simvastatin and Ezetimibe. J Drugs Dermatology 2010;9(1):62-4
   PubMedGoogle Scholar
• CLattouf, JJJimenez, ATosti, et al. Treatment of alopecia areata with simvastatin/ezetimibe. J Am Acad Dermatol 2015;72(2):359-61
   PubMed Web of Science ®Google Scholar
• HMKim, YYLim, MYKim, et al. Inhibitory effect of tianeptine on catagen induction in alopecia areata-like lesions induced by ultrasonic wave stress in mice. Clin Exp Dermatol 2013;38(7):758-67
   PubMedGoogle Scholar